| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Repressor Proteins | 7 | 2022 | 403 | 2.920 |
Why?
|
| Homeodomain Proteins | 7 | 2022 | 536 | 2.770 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2023 | 292 | 2.220 |
Why?
|
| Chromosomes, Human, Pair 7 | 5 | 2022 | 79 | 2.100 |
Why?
|
| Nuclear Proteins | 6 | 2021 | 696 | 1.920 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2023 | 763 | 1.640 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 252 | 1.520 |
Why?
|
| Haploinsufficiency | 5 | 2023 | 62 | 1.490 |
Why?
|
| Killer Cells, Natural | 8 | 2006 | 267 | 1.340 |
Why?
|
| Chromosome Deletion | 4 | 2022 | 229 | 1.120 |
Why?
|
| Transcription Factors | 9 | 2023 | 1565 | 1.110 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2018 | 346 | 1.090 |
Why?
|
| Receptors, Immunologic | 7 | 2006 | 135 | 1.000 |
Why?
|
| Hematopoiesis | 3 | 2018 | 163 | 0.890 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 262 | 0.830 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2022 | 22 | 0.830 |
Why?
|
| Chromosomes, Mammalian | 1 | 2021 | 36 | 0.810 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2021 | 29 | 0.810 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 90 | 0.790 |
Why?
|
| Neoplasms | 7 | 2023 | 2898 | 0.740 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 532 | 0.740 |
Why?
|
| Myeloproliferative Disorders | 1 | 2022 | 110 | 0.730 |
Why?
|
| DNA Repair | 1 | 2021 | 356 | 0.690 |
Why?
|
| Genomics | 3 | 2022 | 720 | 0.660 |
Why?
|
| Mice | 20 | 2023 | 11352 | 0.640 |
Why?
|
| Antigens, CD | 6 | 2005 | 458 | 0.630 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 479 | 0.620 |
Why?
|
| Gene Dosage | 1 | 2018 | 207 | 0.600 |
Why?
|
| Membrane Glycoproteins | 5 | 2005 | 428 | 0.600 |
Why?
|
| Transcription, Genetic | 2 | 2022 | 1135 | 0.580 |
Why?
|
| Leukemia, Myeloid | 2 | 2020 | 249 | 0.570 |
Why?
|
| Gene-Environment Interaction | 1 | 2017 | 103 | 0.570 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 387 | 0.550 |
Why?
|
| Self Tolerance | 2 | 2005 | 24 | 0.520 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 266 | 0.520 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 937 | 0.480 |
Why?
|
| K562 Cells | 3 | 2022 | 43 | 0.470 |
Why?
|
| Animals | 21 | 2023 | 26582 | 0.450 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 878 | 0.410 |
Why?
|
| Erythrocyte Transfusion | 1 | 2010 | 60 | 0.350 |
Why?
|
| CD2 Antigens | 2 | 2006 | 22 | 0.350 |
Why?
|
| Isoantibodies | 1 | 2010 | 114 | 0.340 |
Why?
|
| Humans | 28 | 2023 | 86645 | 0.340 |
Why?
|
| Autoantibodies | 1 | 2010 | 267 | 0.330 |
Why?
|
| Transcriptional Activation | 2 | 2022 | 280 | 0.330 |
Why?
|
| U937 Cells | 2 | 2022 | 32 | 0.320 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2020 | 138 | 0.320 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 131 | 0.320 |
Why?
|
| Mutation | 6 | 2023 | 3968 | 0.300 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 64 | 0.280 |
Why?
|
| Graft Rejection | 3 | 2006 | 1065 | 0.270 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2022 | 157 | 0.260 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2006 | 559 | 0.250 |
Why?
|
| MCF-7 Cells | 2 | 2022 | 106 | 0.240 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 456 | 0.240 |
Why?
|
| NIH 3T3 Cells | 2 | 2022 | 105 | 0.240 |
Why?
|
| Immune Tolerance | 1 | 2006 | 337 | 0.230 |
Why?
|
| Protein Isoforms | 2 | 2022 | 270 | 0.230 |
Why?
|
| Cell Death | 2 | 2021 | 256 | 0.220 |
Why?
|
| HL-60 Cells | 1 | 2022 | 20 | 0.210 |
Why?
|
| Transcription Initiation Site | 1 | 2022 | 45 | 0.210 |
Why?
|
| Gene Editing | 1 | 2022 | 42 | 0.200 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2014 | 279 | 0.200 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 76 | 0.200 |
Why?
|
| Gene Regulatory Networks | 1 | 2023 | 296 | 0.190 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2022 | 105 | 0.190 |
Why?
|
| Heart Transplantation | 1 | 2006 | 705 | 0.190 |
Why?
|
| Mice, Knockout | 6 | 2015 | 1924 | 0.180 |
Why?
|
| Mitoxantrone | 1 | 2020 | 68 | 0.180 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 5 | 2005 | 15 | 0.180 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2005 | 203 | 0.180 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1540 | 0.180 |
Why?
|
| Sulfonamides | 1 | 2021 | 300 | 0.180 |
Why?
|
| Stem Cells | 1 | 2022 | 351 | 0.170 |
Why?
|
| Protein Phosphatase 2C | 1 | 2018 | 3 | 0.170 |
Why?
|
| Cell Proliferation | 3 | 2018 | 1578 | 0.170 |
Why?
|
| Bone Marrow | 1 | 2020 | 435 | 0.160 |
Why?
|
| Genes, Neoplasm | 2 | 2016 | 37 | 0.160 |
Why?
|
| Database Management Systems | 1 | 2018 | 41 | 0.160 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 34 | 0.160 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 2426 | 0.160 |
Why?
|
| Medical Informatics | 1 | 2018 | 47 | 0.160 |
Why?
|
| Cellular Senescence | 1 | 2018 | 94 | 0.150 |
Why?
|
| Consensus Sequence | 1 | 2017 | 64 | 0.150 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 48 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2017 | 24 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 236 | 0.150 |
Why?
|
| Clone Cells | 1 | 2017 | 213 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 109 | 0.150 |
Why?
|
| Inflammation | 2 | 2022 | 920 | 0.150 |
Why?
|
| Anemia | 1 | 2018 | 128 | 0.150 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2017 | 58 | 0.150 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 2232 | 0.140 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 253 | 0.140 |
Why?
|
| Peptide Termination Factors | 1 | 2016 | 5 | 0.140 |
Why?
|
| Nucleic Acid Conformation | 1 | 2017 | 332 | 0.140 |
Why?
|
| Retroviridae | 1 | 2016 | 79 | 0.130 |
Why?
|
| Mutagenesis, Insertional | 1 | 2016 | 111 | 0.130 |
Why?
|
| Risk Factors | 2 | 2017 | 5417 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 91 | 0.130 |
Why?
|
| RNA Interference | 2 | 2014 | 369 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 526 | 0.130 |
Why?
|
| Cell Survival | 1 | 2017 | 969 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 137 | 0.130 |
Why?
|
| Prognosis | 3 | 2017 | 3680 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 388 | 0.120 |
Why?
|
| Major Histocompatibility Complex | 2 | 2005 | 81 | 0.120 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 86 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 154 | 0.120 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 41 | 0.120 |
Why?
|
| Mice, SCID | 2 | 2012 | 252 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 6 | 2015 | 3092 | 0.120 |
Why?
|
| Computer Systems | 1 | 2014 | 79 | 0.120 |
Why?
|
| Datasets as Topic | 1 | 2014 | 71 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 379 | 0.120 |
Why?
|
| Hematopoietic System | 1 | 2013 | 13 | 0.120 |
Why?
|
| CD48 Antigen | 4 | 2005 | 11 | 0.120 |
Why?
|
| Protein Binding | 1 | 2017 | 1456 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 1384 | 0.110 |
Why?
|
| Base Sequence | 1 | 2017 | 2330 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2015 | 195 | 0.110 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 12 | 0.110 |
Why?
|
| Genes, ras | 1 | 2013 | 96 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 2271 | 0.110 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 71 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 187 | 0.110 |
Why?
|
| DNA Damage | 1 | 2014 | 366 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 2903 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 503 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2013 | 327 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 265 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1197 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2012 | 498 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 458 | 0.100 |
Why?
|
| Blotting, Western | 1 | 2012 | 782 | 0.100 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 194 | 0.100 |
Why?
|
| Acute Disease | 1 | 2012 | 826 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 427 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 879 | 0.090 |
Why?
|
| RNA | 1 | 2014 | 560 | 0.090 |
Why?
|
| Laryngeal Edema | 1 | 2010 | 7 | 0.090 |
Why?
|
| Hemagglutinins | 1 | 2010 | 19 | 0.090 |
Why?
|
| Proteins | 1 | 2016 | 777 | 0.090 |
Why?
|
| Acute Chest Syndrome | 1 | 2010 | 16 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 2360 | 0.090 |
Why?
|
| Death, Sudden | 1 | 2010 | 40 | 0.090 |
Why?
|
| Immunization | 1 | 2010 | 158 | 0.090 |
Why?
|
| Software | 1 | 2014 | 654 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2010 | 293 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2010 | 202 | 0.080 |
Why?
|
| Drosophila melanogaster | 1 | 2012 | 599 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2005 | 213 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2013 | 3241 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1196 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2006 | 1047 | 0.070 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 20 | 0.070 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2006 | 29 | 0.070 |
Why?
|
| Antigens, Ly | 1 | 2006 | 37 | 0.070 |
Why?
|
| Genes, MHC Class I | 1 | 2006 | 48 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1565 | 0.070 |
Why?
|
| Sialic Acids | 1 | 2005 | 18 | 0.070 |
Why?
|
| Transplantation, Isogeneic | 1 | 2005 | 39 | 0.070 |
Why?
|
| Receptors, Antigen | 1 | 2005 | 11 | 0.070 |
Why?
|
| beta 2-Microglobulin | 1 | 2005 | 24 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 107 | 0.070 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2005 | 4 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2005 | 728 | 0.070 |
Why?
|
| Lectins | 1 | 2005 | 84 | 0.060 |
Why?
|
| Pneumonia, Viral | 1 | 2010 | 316 | 0.060 |
Why?
|
| Calcium Signaling | 1 | 2005 | 129 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 163 | 0.060 |
Why?
|
| Melanoma, Experimental | 1 | 2005 | 103 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2005 | 148 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 286 | 0.060 |
Why?
|
| Autoimmunity | 1 | 2005 | 160 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2005 | 234 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 996 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 286 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 325 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 425 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2010 | 3613 | 0.060 |
Why?
|
| Ethylnitrosourea | 1 | 2022 | 30 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2022 | 54 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2022 | 158 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2000 | 69 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2020 | 109 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 329 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2000 | 106 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2000 | 192 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 222 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2017 | 1981 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2000 | 165 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2020 | 143 | 0.040 |
Why?
|
| Cytarabine | 1 | 2020 | 218 | 0.040 |
Why?
|
| Azacitidine | 1 | 2020 | 137 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2005 | 813 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2000 | 206 | 0.040 |
Why?
|
| Aged | 3 | 2022 | 18415 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2022 | 535 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 722 | 0.040 |
Why?
|
| Phenotype | 2 | 2014 | 2378 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 645 | 0.040 |
Why?
|
| Male | 5 | 2014 | 40967 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2016 | 20 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 92 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 418 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2016 | 38 | 0.040 |
Why?
|
| Benchmarking | 1 | 2016 | 78 | 0.040 |
Why?
|
| Reference Standards | 1 | 2016 | 159 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 144 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2016 | 229 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 201 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 171 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 217 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1683 | 0.030 |
Why?
|
| Alkylation | 1 | 2014 | 31 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 677 | 0.030 |
Why?
|
| Female | 6 | 2017 | 44534 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 1195 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 1208 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 121 | 0.030 |
Why?
|
| Systems Integration | 1 | 2014 | 35 | 0.030 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2013 | 15 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 276 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 41 | 0.030 |
Why?
|
| Heterozygote | 1 | 2014 | 365 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 790 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2014 | 504 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1041 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 114 | 0.030 |
Why?
|
| Interleukin-2 | 2 | 2005 | 249 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2013 | 153 | 0.030 |
Why?
|
| Genome, Human | 1 | 2017 | 756 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1991 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2705 | 0.030 |
Why?
|
| Internet | 1 | 2014 | 312 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 2767 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1538 | 0.020 |
Why?
|
| Adult | 3 | 2017 | 25648 | 0.020 |
Why?
|
| Cell Line | 2 | 2005 | 2468 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2011 | 628 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6509 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2005 | 18 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 2005 | 57 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2005 | 72 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2005 | 171 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 1830 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1621 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 444 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 896 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2005 | 319 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2357 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 25028 | 0.010 |
Why?
|
| Calcineurin | 1 | 2000 | 16 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2000 | 29 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2000 | 36 | 0.010 |
Why?
|
| Abatacept | 1 | 2000 | 83 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 2000 | 30 | 0.010 |
Why?
|
| Tyrosine | 1 | 2000 | 133 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 2000 | 88 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 2000 | 135 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2000 | 141 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 132 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2000 | 152 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 692 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2000 | 372 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2000 | 1106 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2000 | 409 | 0.010 |
Why?
|
| Adolescent | 1 | 2000 | 8982 | 0.000 |
Why?
|